Proxy Results Form 8 K

On September 24, 2024, Windtree Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") virtually. As of August 28, 2024, the record date for the Annual Meeting, there were 591,909 outstanding shares of the Company's common stock. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in the Company's Definitive Proxy Statement on Schedule 14A for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on September 3, 2024.

The votes with respect to the election of four directors to hold office until the 2025 annual meeting were as follows:

The votes with respect to the approval, on an advisory basis, of the compensation of the Company's named executive officers were as follows:

The votes with respect to the ratification of appointment of EisnerAmper LLP as the Company's Independent Registered Public Accounting Firm for 2024 were as follows:

The votes with respect to the approval of the issuance of shares of common stock, in accordance with Nasdaq Listing Rule 5635(d), pursuant to the Committed Equity Financing were as follows:

The votes with respect to the approval of the issuance of shares of common stock, in accordance with Nasdaq Listing Rule 5635(d), upon (i) the conversion of the Company's Series C Convertible Preferred Stock with an initial conversion price of $3.74, which is subject to adjustment to no lower than $1.28 per share, and (ii) the exercise of warrants to purchase common stock issued in connection therewith, with an initial exercise price of $4.11, subject to customary adjustments, were as follows: